Showing 3951-3960 of 6035 results for "".
- EyeDura's Sustained-Release Eye Drop Technology Wins Industry Honorshttps://modernod.com/news/eyeduras-sustained-release-eye-drop-technology-wins-industry-honors/2482886/EyeDura Therapeutics, developer of preservative-free sustained release ophthalmic therapies, announced it received top recognition at two major industry forums among a field of ophthalmic startup companies. EyeDura won 'The Winning Pitch' challeng
- Nanoscope Initiates Rolling Submission of BLA to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat RPhttps://modernod.com/news/nanoscope-initiates-rolling-submission-of-bla-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-rp/2482884/Nanoscope Therapeutics announced the initiation of a rolling submission of a biologics license application (BLA) to the FDA for its lead investigational therapy, MCO-010, for the treatment of severe vision loss due to retinitis pigmentosa (RP). This marks a significant re
- The Vision Council Comments on Impact of Proposed Tariffs on Optical Industryhttps://modernod.com/news/the-vision-council-comments-on-impact-of-proposed-tariffs-on-optical-industry/2482880/The Vision Council has released a letter summarizing the recent tariffs proposed by the Trump administration and the impact it could have on the optical industry. The White House issued formal notice to several US trading partners outlining tariff
- Johnson & Johnson Appoints Kelly Heaps, Vice President of US Sales, Vision Carehttps://modernod.com/news/johnson-johnson-appoints-kelly-heaps-vice-president-of-us-sales-vision-care/2482879/Johnson & Johnson announced the appointment of Kelly Heaps as Vice President of US Sales, Vision Care. As the leader of the US Sales Organization, Ms. Heaps will work to accelerate sales and foster market share growth while collaborating with customers to strengthen patient outcomes.
- BlueRock Therapeutics Announces First Patient Treated in Phase 1/2a Trial of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-announces-first-patient-treated-in-phase-12a-trial-of-opct-001-for-primary-photoreceptor-diseases/2482877/Bayer and BlueRock Therapeutics announced that the first patient received the investigational therapy in CLARICO, a phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-00
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized
- Bausch + Lomb Launches Dry Eye Education Campaignhttps://modernod.com/news/bausch-lomb-launches-dry-eye-education-campaign/2482872/Bausch + Lomb announced the launch of “Eyes Tell the Story: The Impact of Dry Eye,” a new awareness campaign designed to spotlight the burden of dry eye symptoms through storytelling, photography, and insights from the company’s latest nationw
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Monthshttps://modernod.com/news/the-european-commission-ec-approves-eylea-8-mg-for-extended-treatment-intervals-of-up-to-6-months/2482867/The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously
- Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-presents-positive-interim-phase-2-results-for-subcutaneous-migaldendranib-treatment-for-dme-and-wet-amd/2482864/Ashvattha Therapeutics announced interim results from its ongoing phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The data were presented at the MaculArt Meeting, June 29–July 1, 2025